Quality by Design from Concept to Clinic: Building Quality Into Biologics From Day One

For much of the pharmaceutical industry's history, quality was something you tested for. A batch was manufactured, samples were pulled, specifications were checked, and the batch either passed or it did not. Quality was a verdict delivered at the end.

Quality by Design inverts that logic. Rather than inspecting quality into a product after the fact, QbD builds it in from the beginning - by understanding, before commercial manufacturing starts, exactly which attributes matter to the patient and which process conditions control them.

The distinction sounds philosophical. In practice it determines whether a program spends its later years explaining variability or preventing it.

Start from the patient, not the process

A QbD program begins by asking what the product must do for the patient, then working backwards. That produces a quality target product profile, from which critical quality attributes are derived: the physical, chemical and biological properties that must be controlled because they affect safety or efficacy.

For a biologic, these typically include aggregation, charge variants, glycosylation profile, potency and impurity levels. The important discipline is selectivity. An attribute is critical because there is a mechanistic or clinical reason it matters - not because it is measurable, and not because a previous program measured it.

Over-designating attributes as critical is not a conservative safe choice. It dilutes attention across a long list and generates control obligations that consume resource without protecting patients.

Connect attributes to parameters - with evidence

The core scientific work of QbD is establishing which process parameters actually influence which quality attributes, and how strongly. This is where Design of Experiments earns its place.

One-factor-at-a-time experimentation is intuitive but structurally blind: it cannot detect interactions, and interactions are where biologics processes hide their surprises. A pH change may be harmless at one temperature and consequential at another; a DoE reveals that, a sequential parameter sweep does not.

The output is a design space - the multidimensional region of parameter combinations demonstrated to deliver acceptable quality. Operating within that space is not a leap of faith; it is a claim supported by data, and it is the foundation of the regulatory argument later.

Let the control strategy follow the evidence

With attributes and parameters connected, a control strategy becomes a derivation rather than a judgement call. Parameters demonstrated to affect critical quality attributes are controlled tightly and monitored closely. Parameters shown to have negligible influence are not.

This is where QbD delivers its most tangible operational benefit. A control strategy built on evidence is simpler than one built on caution, because caution has no principled stopping point - every uncertain parameter attracts a control, and controls accumulate into an operating burden that slows every batch for the rest of the product's life.

Why early investment pays

QbD front-loads effort. Development takes more thought, more designed experimentation, and more analytical work before the first clinical batch. Programs under funding pressure reasonably ask whether that investment is affordable.

The evidence generally says the investment is recovered several times over:

• Scale-up is less surprising. A process characterized across a design space behaves predictably at larger scale, because the effect of the parameters that change with scale is already known.
• Validation is a demonstration, not a discovery. PPQ confirms understanding that already exists rather than generating it under time pressure.
• Changes become manageable. Post-approval changes within an established design space are far simpler to justify than changes to a process no one fully characterized.
• Deviations are cheaper. When a parameter drifts, process understanding answers does this matter? in hours rather than weeks.

QbD as a way of working

The most successful QbD programs do not treat it as a documentation exercise satisfied by a section in a filing. They treat it as a way of working: hypotheses stated before experiments, experiments designed to be informative rather than confirmatory, and results integrated into a growing model of how the process behaves.

That habit compounds. Each study makes the next one better targeted, and knowledge accumulates into genuine platform expertise rather than a stack of individual reports.

Quality built in from day one is not a slogan. It is a decision about where to spend effort - early, where it is cheap and generative, rather than late, where it is expensive and merely corrective.

---

Rentschler Biopharma applies Quality by Design principles across process, analytical and formulation development. To discuss a QbD-based development strategy, contact our Business Development team.